- $15.57bn
- $14.73bn
- $2.32bn
U.S. STOCKS ON THE MOVE --Yarrow Bioscience, Chewy, GameStop
U.S. STOCKS ON THE MOVE-GameStop, Kroger, Rocket Lab
U.S. STOCKS ON THE MOVE-Oracle, Oklo, Kroger
Exelixis falls as US FDA extends cancer drug review
US FDA extends review of Exelixis' cancer drug (updated)
U.S. FDA extends review of Exelixis' cancer drug
Brief: Exelixis Says U.S. Court Of Appeals For Federal Circuit Affirms Key Portion Of 2024 Judgment In Co's Favor
U.S. RESEARCH ROUNDUP-Airbnb, Expedia Group, Parker-Hannifin
Exelixis Inc reports results for the quarter ended March 31 - Earnings Summary
Exelixis Q2 revenue misses analyst estimates, lowers 2026 outlook
Brief: Exelixis Q2 Revenue USD 628.7 Million Vs. IBES Estimate USD 636 Million
Exelixis Inc expected to post earnings of 79 cents a share - Earnings Preview
Brief: Exelixis Says Cabometyx Reduces Risk Of Progression Or Death By 74% In Non-Functional Net, 60% In Functional Net
Exelixis Q1 revenue slightly beats estimates
Brief: Exelixis Q1 Revenue USD 610.8 Million Vs. IBES Estimate USD 605.2 Million
Oncology company Exelixis Q4 revenue slightly misses estimates
Brief: Exelixis Q4 Revenue USD 599 Million Vs. IBES Estimate USD 604.2 Million
U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday
Brief: Exelixis Says Fiscal Year 2026 Net Product Revenues Guidance Of $2.325 Billion - $2.425 Billion